ଭୋସୋରିଟାଇଡ

ଭୋସୋରିଟାଇଡ
Clinical data
Trade namesVoxzogo
SynonymsBMN-111
AHFS/Drugs.commonograph
data
Pregnancy
category
Routes of
administration		Subcutaneous injection
Legal status
Legal status
Chemical and physical data
FormulaC176H290N56O51S3
Molar mass୪,୧୦୨.୭୮ g·mol−1
3D model (JSmol)
  • CC[C@H](C)[C@H]1C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)CCCNC(=N)N)CC(=O)O)CC(C)C)CCCCN)CC(C)C)Cc2ccccc2)NC(=O)CNC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](C)NC(=O)CNC(=O)[C@H](CCCCN)NC(=O)[C@H](Cc3ccc(cc3)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)N)NC(=O)[C@@H]4CCCN4C(=O)[C@H](Cc5cnc[nH]5)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)CNC(=O)[C@@H]6CCCN6)C(=O)O)CC(C)C)CO)CCSC)CO
  • InChI=1S/C176H290N56O51S3/c1-14-95(10)143-172(280)201-84-138(245)209-125(86-234)168(276)221-113(54-65-284-13)159(267)229-124(85-233)152(260)200-81-135(242)206-114(66-91(2)3)150(258)198-83-140(247)211-128(174(282)283)89-286-285-88-127(170(278)224-118(70-98-34-16-15-17-35-98)151(259)199-80-137(244)207-115(67-92(4)5)162(270)217-108(41-23-29-60-182)155(263)223-117(69-94(8)9)164(272)226-122(75-142(250)251)167(275)219-110(160(268)231-143)44-32-63-193-176(188)189)210-139(246)82-197-149(257)105(38-20-26-57-179)215-169(277)126(87-235)230-163(271)116(68-93(6)7)208-136(243)79-196-147(255)103(36-18-24-55-177)213-153(261)106(39-21-27-58-180)218-166(274)121(74-132(185)239)222-144(252)96(11)203-133(240)77-195-148(256)104(37-19-25-56-178)214-165(273)119(71-99-46-48-101(236)49-47-99)225-156(264)107(40-22-28-59-181)216-154(262)109(43-31-62-192-175(186)187)212-145(253)97(12)204-161(269)120(73-131(184)238)227-171(279)129-45-33-64-232(129)173(281)123(72-100-76-190-90-202-100)228-158(266)112(51-53-141(248)249)220-157(265)111(50-52-130(183)237)205-134(241)78-194-146(254)102-42-30-61-191-102/h15-17,34-35,46-49,76,90-97,102-129,143,191,233-236H,14,18-33,36-45,50-75,77-89,177-182H2,1-13H3,(H2,183,237)(H2,184,238)(H2,185,239)(H,190,202)(H,194,254)(H,195,256)(H,196,255)(H,197,257)(H,198,258)(H,199,259)(H,200,260)(H,201,280)(H,203,240)(H,204,269)(H,205,241)(H,206,242)(H,207,244)(H,208,243)(H,209,245)(H,210,246)(H,211,247)(H,212,253)(H,213,261)(H,214,273)(H,215,277)(H,216,262)(H,217,270)(H,218,274)(H,219,275)(H,220,265)(H,221,276)(H,222,252)(H,223,263)(H,224,278)(H,225,264)(H,226,272)(H,227,279)(H,228,266)(H,229,267)(H,230,271)(H,231,268)(H,248,249)(H,250,251)(H,282,283)(H4,186,187,192)(H4,188,189,193)/t95-,96-,97-,102-,103-,104-,105-,106-,107-,108-,109-,110-,111-,112-,113-,114-,115-,116-,117-,118-,119-,120-,121-,122-,123-,124-,125-,126-,127-,128-,129-,143-/m0/s1
  • Key:IGYWDDBBJPSOTG-WBAGYEQSSA-N

ଭୋସୋରିଟାଇଡ, ଭକ୍ସଜୋଗୋରେ ବିକ୍ରୟ ନାମ, ହେଉଛି ଆକଣ୍ଡ୍ରୋପ୍ଲାସିଆ (ଡାର୍ଫିଜିମ୍) ରୋଗର ଚିକିତ୍ସା ପାଇଁ ବ୍ୟବହୃତ ଏକ ଔଷଧ ।[୩] [୨] ନିର୍ଦ୍ଦିଷ୍ଟ ଭାବରେ ଏହା ସେହିମାନଙ୍କ ପାଇଁ ବ୍ୟବହୃତ ହୁଏ ଯେଉଁମାନେ ଅତି କମରେ ଦୁଇରୁ ପାଞ୍ଚ ବର୍ଷ ବୟସ୍କ ହୋଇଥାଆନ୍ତି ଏବଂ ତଥାପି ବୃଦ୍ଧି ଚାଲିଥାଏ । [୨] [୩] ଚର୍ମ ତଳେ ଇଞ୍ଜେକସନ ଆକାରରେ ଏହା ଦିଆଯାଏ ।[୨]

ସାଧାରଣ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ଇଞ୍ଜେକସନ ନେଇଥିବା ସ୍ଥାନରେ ଫୁଲା, ଲାଲ ରଙ୍ଗ, ଗଲୁ, ଯନ୍ତ୍ରଣା, ବାନ୍ତି ଏବଂ ନିମ୍ନ ରକ୍ତଚାପ ହୋଇପାରେ । [୩] [୨] ଗର୍ଭାବସ୍ଥାରେ ସୁରକ୍ଷା ଅସ୍ପଷ୍ଟ ଅଟେ ।[୩] ଏହା ଏକ ନାଟ୍ରିୟୁରେଟିକ ପେପ୍ଟାଇଡ ରିସେପ୍ଟର-ବି ନାମକ ଏକ ନିର୍ଦ୍ଦିଷ୍ଟ ରିସେପ୍ଟର ସହିତ ସହିତ ବନ୍ଧନ ଯୁକ୍ତ ହୋଇ କାର୍ଯ୍ୟକ୍ଷମ ହୁଏ ଯାହା ଏଫଜିଏଫଆର୩ (FGFR3)କୁ ହ୍ରାସ କରିବା ଫଳରେ ହାଡ଼ର ବୃଦ୍ଧି ହୁଏ । [୨]

୨୦୨୧ ମସିହାରେ ୟୁରୋପ ଏବଂ ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ଚିକିତ୍ସା କ୍ଷେତ୍ରରେ ବ୍ୟବହାର ପାଇଁ ଭୋସୋରିଟାଇଡ ଅନୁମୋଦିତ ହୋଇଥିଲା ।[୨] [୩] ଫ୍ରାନ୍ସରେ ୨୦୨୨ ସୁଦ୍ଧା ଏହି ଔଷଧ ନିମନ୍ତେ ବାର୍ଷିକ ପ୍ରାୟ ୨୬୦,୦୦୦€ (ଫରାସୀ ମୁଦ୍ରା) ଖର୍ଚ୍ଚ ହୁଏ ।[୫] ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ଏହି ରାଶିର ମୂଲ୍ୟ ପ୍ରାୟ ୩୩୦,୦୦୦ ଡଲାର ଅଟେ ।[୬]

ଆଧାର

[ସମ୍ପାଦନା]
  1. ↑ ୧.୦ ୧.୧ "Voxzogo APMDS". Therapeutic Goods Administration (TGA). 4 August 2022. Archived from the original on 6 August 2022. Retrieved 6 August 2022.
  2. ↑ ୨.୦ ୨.୧ ୨.୨ ୨.୩ ୨.୪ ୨.୫ ୨.୬ "Voxzogo EPAR". European Medicines Agency. 23 June 2021. Archived from the original on 10 September 2021. Retrieved 9 September 2021. Text was copied from this source which is © European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
  3. ↑ ୩.୦ ୩.୧ ୩.୨ ୩.୩ ୩.୪ ୩.୫ "Voxzogo 0.4MG- vosoritide kit Voxzogo 0.56MG- vosoritide kit Voxzogo 1.2MG- vosoritide kit". DailyMed. Archived from the original on 19 December 2021. Retrieved 19 December 2021.
  4. ↑ "FDA Approves First Drug to Improve Growth in Children with Most Common Form of Dwarfism". U.S. Food and Drug Administration (FDA) (Press release). 19 November 2021. Archived from the original on 19 November 2021. Retrieved 19 November 2021.  This article incorporates text from this source, which is in the public domain.
  5. ↑ "Vosoritide". SPS - Specialist Pharmacy Service. 19 December 2019. Archived from the original on 24 October 2022. Retrieved 24 October 2022.
  6. ↑ "Voxzogo". Goodrx. Archived from the original on 24 October 2022. Retrieved 24 October 2022.